San Francisco, CA, October 1, 2013 – America Stem Cell, Inc (ASC) announced that Lynnet Koh, CEO will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 8-9 at the Palace Hotel in San Francisco, Calif.

“ASC was founded with the vision to make stem cell transplantation and cell therapy safer and more efficacious for patients. The profound efficacy and safety results from our current Phase I/IIa trial at M.D. Anderson Cancer Center with ASC-101 in cancer patients undergoing stem cell transplantation is a major step forward in actualizing our vision,” said Lynnet Koh, Chief Executive Officer/Founder of America Stem Cell Inc.

America Stem Cell’s lead product, ASC-101, is a novel enzyme treatment that will potentially transform hematopoietic stem cell transplantation by accelerating patient immune system and platelet recovery, reducing opportunistic infections and other co-morbidities, and improving patient survival. ASC-101 is currently undergoing evaluation in a single-center study at The University of Texas MD Anderson Cancer. To date, 16 patients have been enrolled in the study with 9 patients far enough out to be evaluable for efficacy. Preliminary findings will be presented at the meeting. On the basis of profound data obtained in the single-center study, FDA has given approval to proceed with a multi-center trial.

“Our results are sufficiently robust that we now have received FDA clearance to begin a nationwide, multi-center Phase 1/2a dual-umbilical cord transplantation study evaluating ASC-101 in patients with hematologic malignancies and myelodysplastic syndrome,” said Ms. Koh. Dr. Elizabeth Shpall, Deputy Chairman, Stem Cell Transplantation at MD Anderson Cancer Center and Study Chair of the ASC-101 Phase I/IIa multicenter clinical trial will present the clinical results to date at the upcoming American Society of Hematology (ASH) meeting in New Orleans, in December.

America Stem Cell is a privately-held biotechnology company based in San Antonio, TX, with offices in San Diego, CA, and is dedicated to the development and commercialization of enabling technologies to enhance the efficacy of stem cell therapies. The key technology platforms (ASC-101 and ASC-102) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for patients in need of hematopoietic stem cell transplantation. Additionally, these technologies have the potential to enhance efficacy in stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has partnerships and collaborations with Kyowa Hakko Kirin, Florida Biologix, various medical research institutions including The University of Texas M.D. Anderson Cancer Center, Oklahoma Medical Research Foundation, Fred Hutchinson Cancer Center, University of California San Diego, the Sanford-Burnham Institute, Indiana University, Juvenile Diabetes Research Foundation, as well as corporate partnerships.

Lynnet Koh, CEO
America Stem Cell, Inc.
(760) 612-6277
lkoh@americastemcell.com